Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
93% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. VNDA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VNDA' s Cash to Debt Range Over the Past 10 Years
Min: 5.44  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.62
VNDA's Equity to Asset is ranked lower than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VNDA: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
VNDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.18 Max: 0.94
Current: 0.62
0.01
0.94
Interest Coverage N/A
VNDA's Interest Coverage is ranked lower than
55% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: N/A )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 3
Z-Score: 3.72
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -23.50
VNDA's Operating margin (%) is ranked higher than
63% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. VNDA: -23.50 )
Ranked among companies with meaningful Operating margin (%) only.
VNDA' s Operating margin (%) Range Over the Past 10 Years
Min: -790.41  Med: -36.56 Max: 40
Current: -23.5
-790.41
40
Net-margin (%) -23.07
VNDA's Net-margin (%) is ranked higher than
62% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. VNDA: -23.07 )
Ranked among companies with meaningful Net-margin (%) only.
VNDA' s Net-margin (%) Range Over the Past 10 Years
Min: -788.46  Med: -36.27 Max: 40.25
Current: -23.07
-788.46
40.25
ROE (%) -24.67
VNDA's ROE (%) is ranked higher than
57% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. VNDA: -24.67 )
Ranked among companies with meaningful ROE (%) only.
VNDA' s ROE (%) Range Over the Past 10 Years
Min: -221.21  Med: -78.33 Max: 23.67
Current: -24.67
-221.21
23.67
ROA (%) -15.32
VNDA's ROA (%) is ranked higher than
63% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. VNDA: -15.32 )
Ranked among companies with meaningful ROA (%) only.
VNDA' s ROA (%) Range Over the Past 10 Years
Min: -176.39  Med: -19.36 Max: 12.81
Current: -15.32
-176.39
12.81
ROC (Joel Greenblatt) (%) -743.75
VNDA's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. VNDA: -743.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VNDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4620.09  Med: -1444.21 Max: 784.55
Current: -743.75
-4620.09
784.55
Revenue Growth (3Y)(%) 30.90
VNDA's Revenue Growth (3Y)(%) is ranked higher than
82% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. VNDA: 30.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VNDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 90.4
Current: 30.9
0
90.4
EBITDA Growth (3Y)(%) -13.00
VNDA's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. VNDA: -13.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VNDA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -22.15 Max: -9.1
Current: -13
EPS Growth (3Y)(%) -2.40
VNDA's EPS Growth (3Y)(%) is ranked higher than
52% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. VNDA: -2.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VNDA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -36.9 Max: -2.4
Current: -2.4
» VNDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

VNDA Guru Trades in Q4 2015

Jim Simons 337,390 sh (New)
Paul Tudor Jones 43,204 sh (+5.95%)
John Paulson 3,946,500 sh (unchged)
Steven Cohen Sold Out
» More
Q1 2016

VNDA Guru Trades in Q1 2016

Jim Simons 416,900 sh (+23.57%)
Paul Tudor Jones Sold Out
John Paulson 3,927,000 sh (-0.49%)
» More
Q2 2016

VNDA Guru Trades in Q2 2016

Joel Greenblatt 14,304 sh (New)
Paul Tudor Jones 12,719 sh (New)
John Paulson 3,864,717 sh (-1.59%)
Jim Simons 151,050 sh (-63.77%)
» More
Q3 2016

VNDA Guru Trades in Q3 2016

Steven Cohen 542,700 sh (New)
Paul Tudor Jones 48,953 sh (+284.88%)
Jim Simons 432,050 sh (+186.03%)
Joel Greenblatt 27,244 sh (+90.46%)
John Paulson 2,175,000 sh (-43.72%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:BPMUF, NAS:RPTP, NAS:AMRI, NAS:PACB, NAS:ARDX, NAS:TBRA, OTCPK:IPHYF, NAS:ANIP, NAS:CLCD, NAS:GBT, NAS:MACK, NAS:ANIK, NAS:EPZM, NAS:KERX, NAS:LOXO, NAS:NTLA, NAS:NK, NAS:PGNX, NAS:VTAE, NAS:ACHN » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders such as HETLIOZ, Fanapt and VLY-686.

Vanda Pharmaceuticals Inc was incorporated in Delaware on November 13, 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. Its product portfolio includes HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt (iloperidone) a product for the treatment of schizophrenia, the oral formulation; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase (HDAC) inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities. The Company faces competition from competitors including Sunovion Pharmaceuticals Inc., Pfizer Inc., Takeda Pharmaceuticals Company Limited, Pernix Therapeutics, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd, Neurim Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Alkermes, Inc and Actavis PLC. The Company's business is subject to extensive government regulation and oversight.

Ratios

vs
industry
vs
history
P/B 5.33
VNDA's P/B is ranked lower than
66% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. VNDA: 5.33 )
Ranked among companies with meaningful P/B only.
VNDA' s P/B Range Over the Past 10 Years
Min: 2.53  Med: 5.77 Max: 623.46
Current: 5.33
2.53
623.46
P/S 4.83
VNDA's P/S is ranked higher than
71% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. VNDA: 4.83 )
Ranked among companies with meaningful P/S only.
VNDA' s P/S Range Over the Past 10 Years
Min: 2.63  Med: 6.04 Max: 69.88
Current: 4.83
2.63
69.88
Current Ratio 3.36
VNDA's Current Ratio is ranked lower than
58% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. VNDA: 3.36 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.73 Max: 18.62
Current: 3.36
1.67
18.62
Quick Ratio 3.35
VNDA's Quick Ratio is ranked lower than
56% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. VNDA: 3.35 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.73 Max: 18.62
Current: 3.35
1.64
18.62
Days Inventory 22.29
VNDA's Days Inventory is ranked higher than
87% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. VNDA: 22.29 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s Days Inventory Range Over the Past 10 Years
Min: 22.29  Med: 190.04 Max: 596.04
Current: 22.29
22.29
596.04
Days Sales Outstanding 41.64
VNDA's Days Sales Outstanding is ranked higher than
67% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. VNDA: 41.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.22  Med: 21.88 Max: 253.93
Current: 41.64
5.22
253.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.90
VNDA's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. VNDA: -14.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VNDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.8  Med: -5.9 Max: 0
Current: -14.9
-43.8
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.83
VNDA's Price/Net Cash is ranked lower than
67% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. VNDA: 10.83 )
Ranked among companies with meaningful Price/Net Cash only.
VNDA' s Price/Net Cash Range Over the Past 10 Years
Min: 0.31  Med: 8.21 Max: 1625
Current: 10.83
0.31
1625
Price/Net Current Asset Value 7.54
VNDA's Price/Net Current Asset Value is ranked lower than
61% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. VNDA: 7.54 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VNDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.3  Med: 7.37 Max: 185
Current: 7.54
0.3
185
Price/Tangible Book 6.90
VNDA's Price/Tangible Book is ranked lower than
67% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. VNDA: 6.90 )
Ranked among companies with meaningful Price/Tangible Book only.
VNDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 5.51 Max: 356.36
Current: 6.9
0.29
356.36
Price/Median PS Value 0.80
VNDA's Price/Median PS Value is ranked higher than
61% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. VNDA: 0.80 )
Ranked among companies with meaningful Price/Median PS Value only.
VNDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1 Max: 11.03
Current: 0.8
0.48
11.03
Earnings Yield (Greenblatt) (%) -5.95
VNDA's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. VNDA: -5.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VNDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6  Med: 34.4 Max: 3521.3
Current: -5.95
-6
3521.3

More Statistics

Revenue (TTM) (Mil) $139.6
EPS (TTM) $ -0.75
Beta1.29
Short Percentage of Float7.27%
52-Week Range $6.91 - 18.00
Shares Outstanding (Mil)43.95

Analyst Estimate

Dec16 Dec18
Revenue (Mil $) 149 276
EPS ($) -0.27 2.29
EPS w/o NRI ($) -0.27 2.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate Dec 05 2016
bluebird Stock Up on Positive Interim Multiple Myeloma Data Dec 02 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Dec 02 2016
Heat Biologics Stock Falls on Negative Bladder Cancer Data Dec 01 2016
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S. Dec 01 2016
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors Dec 01 2016
Cytori Scleroderma Study Two-Year Follow-Up Data Published Nov 30 2016
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease Nov 30 2016
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 14.3% Nov 30 2016
Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth Nov 29 2016
Hedge Funds Are Betting On Vanda Pharmaceuticals Inc. (VNDA) Nov 28 2016
Aduro Reports Partial Hold Lift on LADD Studies in U.S. Nov 22 2016
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
Bristol-Myers Offers Updates from Opdivo Combination Trials Nov 14 2016
Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences Nov 14 2016
Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences Nov 14 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Nov 11 2016
VANDA PHARMACEUTICALS INC. Financials Nov 09 2016
Coverage initiated on Vanda Pharma by Aegis Capital Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)